6 Future directions in DKD treatment 6.1 Targeting metabolic, inflammatory, and fibrotic pathways The progression of DKD arises from intricate interactions between metabolic dysregulation, chronic inflammation, and renal fibrosis
Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone released by L-cells in the small intestine in response to food intake
10 , S1802S1807
COVID induces lymphocyte dysfunction, cytokine shifts, endothelial activation, and systemic inflammatory stress
Six-week-old male C57BL/6 J mice were purchased from Taiwan National Laboratory Animal Center
Cordain L, Watkins B, Florant G, Kelher M, Rogers L, Li Y